Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
141 hedge funds and large institutions have $1.38B invested in Esperion Therapeutics in 2015 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 45 increasing their positions, 26 reducing their positions, and 7 closing their positions.
814% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 7
246% more capital invested
Capital invested by funds: $398M → $1.38B (+$979M)
73% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 26
68% more funds holding
Funds holding: 84 → 141 (+57)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
7% more call options, than puts
Call options by funds: $46.4M | Put options by funds: $43.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
+$77.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$50.7M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$50.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$20.5M |
| 5 |
CCI
Columbus Circle Investors
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$19.5M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$15.9M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$11.2M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$9.78M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$6.11M |
ESPR Hedge Fund Activity: Q1 2015 in Review
141 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q1 2015, worth a combined $1.38B — up 246% from $398M a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new ESPR positions and 7 closed out — a net gain of 57 holders — while 45 added to existing stakes and 26 trimmed.
The largest buyer was Visium Asset Management, adding an estimated $77.7M. The largest seller was Perceptive Advisors, cutting an estimated $19.5M.
- 141 institutional investors held Esperion Therapeutics (ESPR) as of Q1 2015, up from 84 in Q4 2014.
- Funds reported $1.38B of Esperion Therapeutics stock for Q1 2015, up 246% quarter-over-quarter.
- 64 funds opened new Esperion Therapeutics positions in Q1 2015 and 7 closed out, a net change of +57 holders.
- The largest Esperion Therapeutics buyer in Q1 2015 was Visium Asset Management, an estimated $77.7M added.
- The largest Esperion Therapeutics seller in Q1 2015 was Perceptive Advisors, an estimated $19.5M sold.
Based on aggregated 13F filings for Q1 2015.